Drug Name & Action

Pioneer Product Name

Approx Sales

UK SPC No. & Expiry Date

Irish SPC No. & Expiry date

US Patent No. & Expiry Date Inc. Extension

Abacavir

(HIV)

Ziagen®

$0.1bn

27 June 2014

SPC/2001/012

27 June 2014

DS7XHPI

18 Dec 2011

Abciximab or c7E3 Fab

 (cardiac ischaemia)

ReoPro®

$0.35 bn

SPC/GB02/039

10 Nov 09

No Basic Irish Patent

US5770198

23 June 15

Adalimumab

(Auto immune disease, anti TNF alpha)

HUMIRA®

$1.0bn

SPC/GB04/006

12 December 2010

No Basic Irish Patent

US6090923 

13 December 2016

Atorvastatin

(Hypercholesteremia)

Liptor®

$13bn

SPC/GB97/011

6 Nov 2011

SPC/1998/005

06 November 2011

US4681893

24 Sept 09

Becaplermin

(diabetic foot Ulcers)

Regranex®

$0.1bn

SPC/GB99/023

9 Oct 2010

No Basic Irish Patent 

US4845075 

29 Oct 10

Ceftiofur

(Antibiotic)

Excenel®

$0.1bn

SPC/GB99/023

14 Oct 2010

No Basic Irish Patent 

US4902683

25 May 08 

Clopidogrel

(anti blood coagulation)

Plavix®

$4bn

SPC/GB99/001

15 Feb 13

SPC/1998/022

31 January 2013

US4847265

17 Nov 11

Desloratadine

(anti histamine)

Clarinex®

$0.5bn

SPC/GB01/012

11 Feb 10

No Irish SPC

Basic Irish Patent Expired

13 May 2006

US4659716

31 March 07

Donepezil

(Reduce Alzheimers Symptoms)

Aricept®

$3.5bn

SPC/GB97/023

13 Feb 12

No Basic Irish Patent

US4847265

25 Nov 10

Esomeprazole (Mg salt)

(Proton Pump Inhibitor, anti Ulcer)

Nexium®

$5bn

SPC/GB01/006

27 Feb 09

SPC/2000/025

01 March 2009

US4738974

1 Sept 07

Lamivudine 

(Hepatitis B and HIV)

Epivir®

$0.5bn

SPC/GB96/043

27 Feb 11

SPC/1997/015

27 Feb 2011

US5047407

17 Nov 09

Insulin lispro

 (Diabetes)

Humalog®

$5bn

SPC/GB96/036

22 Nov 2010

SPC/1997/016

22/11/2010

US5514646 

07 May 2013

Lercanidipine Hydrochloride

(Hyperstension)

Zandip®

$0.25 bn

SPC/GB/96/018

20 Jan 10

SPC/024/2001 

05 Feb 2010

US4705797

21 Jan 05

Imatinib

(Anti-Cancer, CML and GIT)

Gleevec®/Glivec® 

$4bn

SPC/GB02/016

20 June 16

SPC/2002/005

20 June 2016

US5521184

04 Jan 15

Levofloxacin

(antibiotic, lung infections)

Levaquin®

$1.4bn

SPC/GB06/025

19 June 11

SPC/1998/009

18 June 2011

US5053407

20 Dec 2010

Moroctocog alfa

(Antihemophilic factor)

ReFacto®

$0.1bn

SPC/GB03/013

10 Jan 2010

No Basic Irish Patent

US48681124

28 Feb 10

Natalizumab 

(Multiple Sclelrosis)  

Tysabri®

$0.9bn

SPC/GB06/025

24 January 2020

SPC/2006/025

24 Jan 2020

US5840299

27 April 2017

Pramipexole

(anti-Parkinsons)

Mirapexin® Mirapex®

$0.8bn

SPC/GB98/017

15 Dec 2010

SPC/1998/001

19 Dec 2010

US4886812

25 March 2011

Pioglitazone

(Diabetes)

Actos®

$5.0bn

SPC/GB01/016

14 January 2011

SPC/ 2001/005

13 January 2011

US4687777 

18 January 2011

Residronate

Bone Disease/Osteoporsis

Actonel®

$2.0bn

SPC/GB00/021

15 December 2010

SPC/2000/016

19 December 2010

US5583122 

10 December 2013

Saquinavir

(HIV)

Invirase®

$3.0bn

SPC/GB97/004

17 January 2011

SPC/ 1996/026

3 October 2011

US5196438

19 November 2010

Sildenafil 

(erectile dysfunction treatment)

Viagra®

$0.9bn

SPC/GB99/004

 21 June 2013

SPC/I1999/004

 20 June 2013

US5250534

 27 March 2012

Zafirlukast

(Asthma)

Accolate®

$0.1bn

SPC/GB98/033

2 January 2011

SPC/ 1996/009

2 January 2011

US4859692 

26 Sept 2010